A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

ERLANGEN, GERMANY AND VILNIUS, LITHUANIA - Mallia Therapeutics, a German biopharmaceutical company, and Northway Biotech, a ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

In modern medicine, alopecia treatment is essential since It reduces hair loss and encourages growth. Minoxidil, finasteride, corticosteroids, 5-alpha reductase inhibitors, and cyclosporine can ...

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

As of 2018, the global alopecia treatment market is expected to reach $3,935 million by 2026, registering a CAGR of 4.6% from 2019 to 2026. WILMINGTON, DE, UNITED STATES, January 29, 2025 ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

Revive thinning edges with expert advice on tailored hair care, treatments, and lifestyle changes designed for women of color.

With Northway Biotech’s expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to ...